-
1.发明授权COMBINATION COMPRISING A SIGNAL TRANSDUCTION INHIBITOR AND AN EPOTHILONE DERIVATIVE 有权组合中包含信号传导和A抑制剂的埃坡霉素衍生物
公开(公告)号：EP1385522B1
公开(公告)日：2009-06-24
申请号：EP02744903.2
申请日：2002-02-26
申请人： NOVARTIS AG , Novartis Pharma GmbH
发明人： BUCHDUNGER, Elisabeth , HELDIN, Carl-Henrik , ÖSTMAN, Arne , PIETRAS, Kristian , O'REILLY, Terence , ROTHERMEL, John, David , TRAXLER, Peter , WARTMANN, Markus , BRANDT, Ralf
IPC分类号： A61K31/505 , A61K45/06 , A61K31/425 , A61P35/00
CPC分类号： A61K31/505 , A61K31/425 , A61K45/06 , A61K31/435 , A61K2300/00
摘要： The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.
-
2.发明公开BIOMARKERS FOR SENSITIVITY OF PROLIFERATIVE DISEASES TO MTOR INHIBITORS 审中-公开生物标记EMPFLINDLICHKEIT增生性疾病AGAINST mTOR抑制剂
公开(公告)号：EP1709449A1
公开(公告)日：2006-10-11
申请号：EP04804145.3
申请日：2004-12-21
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
IPC分类号： G01N33/68 , G01N33/574
CPC分类号： G01N33/5008 , G01N33/5011 , G01N33/5091 , G01N33/574 , G01N33/57496 , G01N33/68 , G01N33/6842 , G01N2800/52
摘要： Disclosed is a method for determining the sensitivity of a proliferate disease in a subject to treatment with an mTOR inhibitor, comprising determining the level of expression and/or phosphorylation state of S6 in a sample derived from the subject, as well as related methods of treatment and uses.
-
公开(公告)号：EP1339411A2
公开(公告)日：2003-09-03
申请号：EP01998352.7
申请日：2001-11-27
申请人： Novartis AG , Novartis Pharma GmbH
发明人： FOX, Alyson,The Novartis Inst. for Med. Sciences , GREEN, Jonathan , O'REILLY, Terence , URBAN, Laszlo,The Novartis Inst. for Medical Sci. , WALKER, Katharine
CPC分类号： A61K31/663
摘要： A method for the treatment of pain, in particular antinociceptive or anti-allodynic treatment of pain, in a patient in need of such treatment, e.g. a patient with osteoporosis or osteopenia, a tumour patient or a patient suffering from an inflammatory disease, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient.
-
4.发明公开P53 WILD-TYPE AS BIOMARKER FOR THE TREATMENT WITH MTOR INHIBITORS IN COMBINATION WITH A CYTOTOXIC AGENT 审中-公开P53野生型作为与mTOR抑制剂治疗的生物标志物结合的细胞毒性剂
公开(公告)号：EP1721007A2
公开(公告)日：2006-11-15
申请号：EP05715457.7
申请日：2005-02-22
申请人： Novartis AG , Novartis Pharma GmbH , Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
发明人： BEUVINK, Iwan , BOULAY, Anne , LANE, Heidi , O'REILLY, Terence , THOMAS, George
IPC分类号： C12Q1/68
CPC分类号： G01N33/5748 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N2800/52
摘要： Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the integrity of DNA.
-
5.发明公开COMBINATION COMPRISING A SIGNAL TRANSDUCTION INHIBITOR AND AN EPOTHILONE DERIVATIVE 有权组合中包含信号传导和A抑制剂的埃坡霉素衍生物
公开(公告)号：EP1385522A2
公开(公告)日：2004-02-04
申请号：EP02744903.2
申请日：2002-02-26
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BUCHDUNGER, Elisabeth , HELDIN, Carl-Henrik , ÖSTMAN, Arne , PIETRAS, Kristian , O'REILLY, Terence , ROTHERMEL, John, David , TRAXLER, Peter , WARTMANN, Markus , BRANDT, Ralf
IPC分类号： A61K31/505 , A61K45/06 , A61K31/425 , A61P35/00
CPC分类号： A61K31/505 , A61K31/425 , A61K45/06 , A61K31/435 , A61K2300/00
摘要： The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.
-
公开(公告)号：EP1056453B1
公开(公告)日：2010-10-06
申请号：EP99910257.7
申请日：1999-02-23
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/425
CPC分类号： A61K31/425
-
公开(公告)号：EP1339411B1
公开(公告)日：2007-07-04
申请号：EP01998352.7
申请日：2001-11-27
申请人： Novartis AG , Novartis Pharma GmbH
发明人： FOX, Alyson, The Novartis Inst. for Med. Sciences , GREEN, Jonathan , O'REILLY, Terence , URBAN, Laszlo, The Novartis Inst. for Medical Sci. , WALKER, Katharine
CPC分类号： A61K31/663
摘要： A method for the treatment of pain, in particular antinociceptive or anti-allodynic treatment of pain, in a patient in need of such treatment, e.g. a patient with osteoporosis or osteopenia, a tumour patient or a patient suffering from an inflammatory disease, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient.
-
8.发明授权COMBINATION COMPRISING N- 5- 4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO|-2-METHYLPHENYL -4-(3-PYRIDYL)-2PYRIMIDINE-AMINE AND A BIPHOSPHONATE 有权COMBINATION N- 5-（4-甲基 - 哌嗪子基 - 甲基） - 苯甲酰胺基具有二膦酸酯-2-甲基-4-（3-吡啶基）-2PYRIMIDINE胺
公开(公告)号：EP1392313B1
公开(公告)日：2007-04-18
申请号：EP02743024.8
申请日：2002-05-15
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BRUNS, Christian , BUCHDUNGER, Elisabeth , O'REILLY, Terence , SILBERMAN, Sandra, Leta , WARTMANN, Markus , WECKBECKER, Gisbert
IPC分类号： A61K31/506 , A61P35/00 , A61P37/06 , A61K31/675
CPC分类号： A61K45/06 , A61K31/506
摘要： A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.
-
9.发明公开COMBINATION COMPRISING N- 5- 4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL -4-(3-PYRIDYL)-2PYRIMIDINE-AMINE AND A CHEMOTHERAPEUTIC AGENT 有权COMBINATION N- 5-（4-甲基 - 哌嗪子基 - 甲基） - 苯甲酰胺基具有二膦酸酯-2-甲基-4-（3-吡啶基）-2PYRIMIDINE胺
公开(公告)号：EP1392313A1
公开(公告)日：2004-03-03
申请号：EP02743024.8
申请日：2002-05-15
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BRUNS, Christian , BUCHDUNGER, Elisabeth , O'REILLY, Terence , SILBERMAN, Sandra, Leta , WARTMANN, Markus , WECKBECKER, Gisbert
IPC分类号： A61K31/506 , A61P35/00 , A61P37/06
CPC分类号： A61K45/06 , A61K31/506
摘要： A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.
-
公开(公告)号：EP1363627A2
公开(公告)日：2003-11-26
申请号：EP02719864.7
申请日：2002-02-18
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/436
CPC分类号： A61K31/436 , A61K31/337 , A61K31/4196 , A61K31/439 , A61K31/4745 , A61K31/475 , A61K31/502 , A61K31/555 , A61K31/5685 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2300/00
摘要： Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.017 秒)
